Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 29 02:48PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.13 Insider Own14.11% Shs Outstand146.38M Perf Week8.73%
Market Cap88.33M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float125.73M Perf Month28.39%
Income-93.09M PEG- EPS next Q-0.07 Inst Own40.81% Short Float8.10% Perf Quarter-36.28%
Sales16.30M P/S5.42 EPS this Y73.64% Inst Trans-6.50% Short Ratio4.98 Perf Half Y-43.60%
Book/sh0.19 P/B3.11 EPS next Y- ROA-99.47% Short Interest10.18M Perf Year-84.74%
Cash/sh0.07 P/C9.17 EPS next 5Y- ROE-188.78% 52W Range0.36 - 3.95 Perf YTD-16.19%
Dividend Est.- P/FCF- EPS past 5Y-19.78% ROI-307.35% 52W High-84.72% Beta-0.23
Dividend TTM- Quick Ratio0.83 Sales past 5Y16.77% Gross Margin45.99% 52W Low67.62% ATR (14)0.06
Dividend Ex-DateApr 28, 2014 Current Ratio1.16 EPS Y/Y TTM-8.19% Oper. Margin-586.26% RSI (14)59.87 Volatility15.57% 11.35%
Employees189 Debt/Eq0.81 Sales Y/Y TTM-58.59% Profit Margin-571.20% Recom1.00 Target Price2.00
Option/ShortYes / Yes LT Debt/Eq0.70 EPS Q/Q76.97% Payout- Rel Volume0.60 Prev Close0.62
Sales Surprise-46.15% EPS Surprise33.33% Sales Q/Q49.19% EarningsFeb 08 BMO Avg Volume2.05M Price0.60
SMA2024.60% SMA5013.18% SMA200-34.03% Trades Volume1,018,847 Change-2.12%
Date Action Analyst Rating Change Price Target Change
Jun-07-23Upgrade Jefferies Underperform → Hold $1
Apr-13-21Initiated Jefferies Buy $19
Feb-09-21Reiterated H.C. Wainwright Buy $12 → $17
Jan-21-20Reiterated H.C. Wainwright Buy $4.50 → $6
Mar-20-19Initiated Oppenheimer Outperform $5
Jul-03-18Initiated Maxim Group Buy
Feb-27-24 07:15PM
Feb-20-24 08:30AM
Feb-13-24 09:35AM
Feb-09-24 10:46AM
Feb-08-24 10:19PM
10:14AM Loading…
Feb-06-24 08:30AM
Feb-01-24 10:00AM
Jan-31-24 08:30AM
Jan-25-24 08:30AM
Jan-08-24 08:30AM
Dec-19-23 08:30AM
Dec-14-23 09:00AM
04:01PM Loading…
Dec-13-23 04:01PM
Dec-07-23 06:00AM
Oct-05-23 07:18AM
Oct-04-23 08:30AM
Sep-26-23 08:30AM
Sep-20-23 08:30AM
Sep-11-23 07:00AM
Aug-30-23 08:30AM
Aug-11-23 08:15AM
Aug-10-23 07:50AM
Aug-03-23 08:30AM
Jun-21-23 08:30AM
Jun-01-23 08:30AM
May-24-23 08:30AM
08:09AM Loading…
May-11-23 08:09AM
May-09-23 11:15AM
May-04-23 10:00AM
May-03-23 08:30AM
Apr-27-23 06:45AM
Apr-20-23 06:45AM
Apr-19-23 08:30AM
Apr-12-23 09:35AM
Apr-11-23 03:49PM
Apr-04-23 08:30AM
Mar-27-23 06:37AM
Mar-14-23 01:36PM
Mar-07-23 08:30AM
Mar-03-23 11:27AM
Mar-02-23 04:01PM
Feb-14-23 06:06AM
Feb-10-23 03:11PM
Feb-09-23 07:45AM
Jan-26-23 08:30AM
Jan-17-23 05:32AM
Jan-10-23 08:30AM
Dec-29-22 05:57AM
Dec-10-22 09:45AM
Dec-08-22 01:59PM
Dec-07-22 08:15AM
Dec-05-22 08:00AM
Dec-02-22 09:00AM
Nov-28-22 08:30AM
Nov-23-22 05:54PM
Nov-22-22 09:15AM
Nov-21-22 06:10PM
Nov-13-22 07:46AM
Nov-11-22 03:15PM
Nov-10-22 04:11PM
Nov-09-22 08:55PM
Nov-08-22 02:56AM
Nov-07-22 04:15PM
Oct-24-22 08:30AM
Oct-13-22 08:30AM
Oct-09-22 09:45AM
Oct-04-22 04:30PM
Sep-26-22 06:45AM
Sep-23-22 07:51AM
Sep-21-22 08:30AM
Sep-19-22 12:15PM
Sep-08-22 07:14AM
Sep-07-22 01:45PM
Sep-06-22 08:30AM
Sep-02-22 10:37AM
Aug-30-22 01:33PM
Aug-28-22 03:07PM
Aug-25-22 10:15AM
Aug-22-22 08:30AM
Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company's drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 clinical trial of enobosarm for the treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The company was founded by William R. Gargiulo, Jr., O. B. Parrish, and Harry Fisch in 1971 and is headquartered in Miami, FL.